[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:smoldering-multiple-myeloma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":152,"states":157},"Smoldering Multiple Myeloma",23,22,[8,16,22,28,35,41,48,54,60,66,72,78,85,91,97,103,109,115,121,127,133,139,145],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06140524","A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma",[12],"Phase 2","RECRUITING","2026-08-26T02:17:12.307088Z","2026-05-05T02:43:29.678975Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05640843","A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)",[],"2026-08-26T02:17:21.315591Z","2026-05-05T02:43:29.570644Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06100237","Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)",[12],"2026-08-26T02:16:24.135291Z","2026-05-05T02:43:29.197990Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT05055063","A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma",[32],"Phase 1","2026-08-26T02:15:43.339060Z","2026-05-05T02:43:27.754318Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05469893","Immuno-PRISM (PRecision Intervention Smoldering Myeloma)",[12],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:27.482255Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT03937635","Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma",[45],"Phase 3","2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.306737Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT04776395","Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma",[12],"2026-08-26T02:19:23.493898Z","2026-04-29T02:57:57.111893Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05597345","Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma",[12],"2026-08-26T02:16:20.336282Z","2026-04-29T02:57:57.111888Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT07446777","FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease",[],"2026-08-26T02:18:15.214990Z","2026-05-05T02:43:28.299468Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT02291848","Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma",[32],"2026-08-03T03:12:56.078888Z","2026-05-05T02:43:26.850250Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06055894","A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)",[],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:27.741887Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":83,"content_modified":84},"NCT05093335","In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET",[82],"Early Phase 1","2026-08-26T02:17:25.718160Z","2026-05-05T02:43:29.185534Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07393282","A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)",[45],"2026-08-26T02:18:20.384845Z","2026-06-14T18:39:22.242948Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06365060","Screening for AL Amyloidosis in Smoldering Multiple Myeloma",[],"2026-08-26T02:18:57.189473Z","2026-05-13T02:55:06.484117Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06212323","Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial",[],"2026-08-26T02:19:28.327680Z","2026-05-13T02:55:06.430766Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT05361694","Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions",[],"2026-08-26T02:18:39.640967Z","2026-05-13T02:55:06.301974Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT05136807","Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies",[],"2026-08-26T02:16:46.147215Z","2026-05-13T02:55:06.293280Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT02726750","Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma",[],"2026-08-26T02:15:34.659160Z","2026-05-13T02:55:06.100287Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06644625","CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study",[],"2026-08-26T02:16:18.872924Z","2026-05-13T02:55:06.559757Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT03717844","Registry for Adults With Plasma Cell Disorders (PCD's)",[],"2026-08-26T02:18:13.438956Z","2026-05-13T02:55:06.175931Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT03616483","The Indiana Myeloma Registry",[],"2026-08-26T02:16:39.977107Z","2026-05-13T02:55:06.173594Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT02269592","Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome",[],"2026-08-26T02:17:58.890423Z","2026-05-13T02:55:06.091298Z",{"nct_id":146,"title":147,"phases":148,"status":149,"updated_at":150,"content_modified":151},"NCT05438043","A Study of Daratumumab",[45],"ACTIVE_NOT_RECRUITING","2026-08-03T03:31:16.569358Z","2026-05-05T02:43:27.757467Z",[153],{"biomarker":154,"count":155,"slug":156},"t(4;14)",3,"t-4-14",[158,162,166,170,173,177,180,184,187],{"state":159,"count":160,"slug":161},"New York",8,"new-york",{"state":163,"count":164,"slug":165},"Texas",7,"texas",{"state":167,"count":168,"slug":169},"Florida",6,"florida",{"state":171,"count":168,"slug":172},"Massachusetts","massachusetts",{"state":174,"count":175,"slug":176},"Georgia",5,"georgia",{"state":178,"count":175,"slug":179},"Michigan","michigan",{"state":181,"count":182,"slug":183},"North Carolina",4,"north-carolina",{"state":185,"count":155,"slug":186},"New Jersey","new-jersey",{"state":188,"count":155,"slug":189},"Utah","utah"]